Lunai Bioworks Reports 98% Reduction in Net Loss for Fiscal Year Ending June 30, 2026

Lunai Bioworks Inc. reported a significant reduction in its net loss for the fiscal year ending June 30, 2026, posting a loss of $3.56 million compared to a loss of $178 million in the previous year, marking a decrease of approximately 98%. The company recognized $51,992 in service revenue from a single research services customer, a notable increase from zero revenue in the prior year. This shift in financial performance is attributed to a substantial decrease in operating expenses, which fell by 95% to $8.75 million, primarily due to the absence of a prior-year goodwill impairment of $170 million and reduced general and administrative costs.

Strategically, Lunai Bioworks has undergone significant organizational changes, including the acquisition of Neurobridge IP Holdings in May 2026, which brought in intellectual property related to an intranasal drug delivery platform. This acquisition was executed through the issuance of Series B Convertible Preferred Stock valued at $20 million, although the acquisition-date fair value was recorded at $1.84 million. The company also streamlined its operations following the bankruptcy of GEDi Cube B.V. in September 2025, focusing on its AI-driven precision medicine and biomarker discovery strategy through its subsidiary BioSymetrics.

Operationally, Lunai Bioworks has maintained a lean workforce, with 12 full-time employees as of June 30, 2026, down from previous levels. The company has emphasized its AI-driven biotechnology platform, which integrates multimodal data analytics with experimental biology to enhance therapeutic development. Despite these efforts, the company continues to face challenges, including a working capital deficit of $16.87 million and a cash balance of $1.71 million, raising concerns about its ability to continue as a going concern without additional financing.

Looking ahead, Lunai Bioworks is actively pursuing additional funding to support its operations and development programs. The company has indicated that it may need to raise substantial capital through equity or debt financing to sustain its operations and continue its research and development activities. However, there is no assurance that such financing will be available on favorable terms, which could significantly impact the company's future operations and financial stability. The management's plans to secure funding are critical, as the company has less than one month of cash resources available as of October 13, 2026.